PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33991465-2	2021	PAI-1-targeted fibrinolytic therapy (PAI-1-TFT) is designed to decrease the therapeutic dose of tPA and uPA, attenuating the risk of bleeding and other complications.	Tetradecanoylphorbol Acetate	96-99	serpin family E member 1	Homo sapiens	0-5	
33991465-2	2021	PAI-1-targeted fibrinolytic therapy (PAI-1-TFT) is designed to decrease the therapeutic dose of tPA and uPA, attenuating the risk of bleeding and other complications.	Tetradecanoylphorbol Acetate	96-99	serpin family E member 1	Homo sapiens	37-42	
33991465-6	2021	PAI-1-TFT with DSP (2.0 mg/kg) converted ineffective doses of single chain (sc) tPA (72.5 microg/kg) and scuPA (62.5 microg/kg) into effective ones in chemically induced pleural injury.	Tetradecanoylphorbol Acetate	80-83	serpin family E member 1	Homo sapiens	0-5